# Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)

> **NCT02832128** · PHASE2 · COMPLETED · sponsor: **Autifony Therapeutics Limited** · enrollment: 15 (actual)

## Conditions studied

- Hearing Loss
- Hearing Impairment

## Interventions

- **DRUG:** AUT00063
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02832128
- **Lead sponsor:** Autifony Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02832128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02832128, "Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02832128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*